<DOC>
	<DOCNO>NCT02931305</DOCNO>
	<brief_summary>The primary objective trial develop Epimedium Prenylflavonoid ( EP ) extract pharmaceutical-quality intervention post-menopausal osteoporosis cardiovascular disease . There 3 cohort 10 healthy men Phase 1 study . In cohort , 8 men receive Epimedium capsule 2 men receive matched control .</brief_summary>
	<brief_title>Epimedium Prenylflavonoid ( EP ) Extract Osteoporosis Cardiovascular Disease</brief_title>
	<detailed_description>Prenylflavonoids glycoside derivative isolated Traditional Chinese Medicine ( TCM ) , Epimedium , potent estrogenic property . The principal bioactive compound Epimedium prenylflavonoids , icaritin , glycosylated derivative enhance osteoblastic differentiation mineralization , inhibit bone resorption , induces apoptosis osteoclast . Animal experiment indicate icariin prevent bone loss induce ovariectomized ( OVX ) rat , stimulatory effect osteoblast growth function , inhibitory action osteoclast cell . Epimedium also demonstrate significant cardiovascular benefit positive action vascular reactivity , endothelial function thrombosis human subject . Notably , icariin , demonstrate significant nitric oxide ( NO ) -dependent vasorelaxation precontracted coronary arterial ring intact endothelium concentration-dependent manner , via activation endothelial nitric oxide synthase protein NO-cyclic guanidine monophosphate ( cGMP ) pathway . Epimedium prenylflavonoids ( EP ) prevent steroid-associated osteonecrosis rabbit model notably , reduce thrombosis incidence shrink fat-cell-size significantly . This striking combination property highlight immense potential EP osteoporosis cardiovascular health .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Healthy men . Hepatitis B patient</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Epimedium prenylflavonoids</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Phase 1</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>